The MPP, through its licensing agreements with ViiV Healthcare, has been facilitating accelerated access to affordable versions of dolutegravir (DTG) since 2014. The World Health Organization recommends DTG-based treatment as an alternative first-line regimen for people living with HIV. The countries benefiting from the licensing agreements account for 94 percent of adults living with HIV in low- and middle-income countries, including: Armenia, Bolivia, India, Malawi, South Africa and Zimbabwe. See agreements in full, plus country list here.
Here are stories and testimonies from people in some of these countries on how being able to access DTG has made a difference to them.